Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A

Microvascular Research

Volumn 84, Issue 3, 2012, Pages 395-398

  Ishibashi, Yuji ^a   Matsui, Takanori ^a   Ojima, Ayako ^a   Nishino, Yuri ^a   Nakashima, Sae ^a   Maeda, Sayaka ^a   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCAGON LIKE PEPTIDE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; SUPEROXIDE; TRANSCRIPTION FACTOR RELA;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DAMAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERCELLULAR ADHESION MOLECULE 1 GENE; MESANGIUM CELL; PLASMINOGEN ACTIVATOR INHIBITOR 1 GENE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCAGON-LIKE PEPTIDE 1; HORMONES; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; ISOQUINOLINES; MESANGIAL CELLS; NF-KAPPA B; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; SULFONAMIDES; UP-REGULATION;

EID: 84868144237     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2012.06.008     Document Type: Article

References (32)

1. Anagnostis P., Athyros V.G., Adamidou F., Panagiotou A., Kita M., Karagiannis A., Mikhailidis D.P. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes. Metab. 2011, 13:302-312.
2. Blumenthal S.S. Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward. Postgrad. Med. 2011, 123:166-179.
3. Chan Y.C., Leung P.S. Angiotensin II type 1 receptor-dependent nuclear factor-kappaB activation-mediated proinflammatory actions in a rat model of obstructive acute pancreatitis. J. Pharmacol. Exp. Ther. 2007, 323:10-18.
4. Chen L., Zhang J., Zhang Y., Wang Y., Wang B. Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats. Inflamm. Res. 2008, 57:199-204.
5. Chilton R., Wyatt J., Nandish S., Oliveros R., Lujan M. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am. J. Med. 2011, 124(1 Suppl.):S35-S53.
6. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006, 69:73-80.
7. Cooper M.E., Jandeleit-Dahm K., Thomas M.C. Targets to retard the progression of diabetic nephropathy. Kidney Int. 2005, 68:1439-1445.
8. Drucker D.J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat. Clin. Pract. Endocrinol. Metab. 2006, 1:22-31.
9. Fukami K., Ueda S., Yamagishi S., Kato S., Inagaki Y., Takeuchi M., Motomiya Y., Bucala R., Iida S., Tamaki K., Imaizumi T., Cooper M.E., Okuda S. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 2004, 66:2137-2147.
10. Hendarto H., Inoguchi T., Maeda Y., Ikeda N., Zheng J., Takei R., Yokomizo H., Hirata E., Sonoda N., Takayanagi R. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 2012, 10.1016/j.metabol.2012.03.002.
11. Herman G.A., Bergman A., Stevens C., Kotey P., Yi B., Zhao P., Dietrich B., Golor G., Schrodter A., Keymeulen B., Lasseter K.C., Kipnes M.S., Snyder K., Hilliard D., Tanen M., Cilissen C., De Smet M., de Lepeleire I., Van Dyck K., Wang A.Q., Zeng W., Davies M.J., Tanaka W., Holst J.J., Deacon C.F., Gottesdiener K.M., Wagner J.A. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2006, 91:4612-4619.
12. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006, 49:253-260.
13. Ide Y., Matsui T., Ishibashi Y., Takeuchi M., Yamagishi S. Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by NF-kappaB activation. Microvasc. Res. 2010, 80:227-232.
14. Ishibashi Y., Nishino Y., Matsui T., Takeuchi M., Yamagishi S. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 2011, 60:1271-1277.
15. Kilpatrick E.S., Rigby A.S., Atkin S.L. The Diabetes Control and Complications Trial: the gift that keeps giving. Nat. Rev. Endocrinol. 2009, 5:537-545.
16. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 2008, 60:470-512.
17. Lee H.B., Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology (Carlton) 2005, S11-S13. (Suppl.).
18. Nishida M., Kitajima N., Saiki S., Nakaya M., Kurose H. Regulation of Angiotensin II receptor signaling by cysteine modification of NF- κB. Nitric Oxide 2011, 25:112-117.
19. Pantano C., Reynaert N.L., van der Vliet A., Janssen-Heininger Y.M. Redox-sensitive kinases of the nuclear factor-kappaB signaling pathway. Antioxid Redox Signal. 2006, 8:1791-1806.
20. Park C.W., Kim H.W., Ko S.H., Lim J.H., Ryu G.R., Chung H.W., Han S.W., Shin S.J., Bang B.K., Breyer M.D., Chang Y.S. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J. Am. Soc. Nephrol. 2007, 18:1227-1238.
21. Remuzzi G., Schieppati A., Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2002, 346:1145-1151.
22. Satriano J., Schlondorff D. Activation and attenuation of transcription factor NF-kB in mouse glomerular mesangial cells in response to tumor necrosis factor-alpha, immunoglobulin G, and adenosine 3':5'-cyclic monophosphate. Evidence for involvement of reactive oxygen species. J. Clin. Invest. 1994, 94:1629-1636.
23. Sugimoto H., Shikata K., Hirata K., Akiyama K., Matsuda M. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 1997, 46:2075-2201.
24. Wei Y., Sowers J.R., Clark S.E., Li W., Ferrario C.M., Stump C.S. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E345-E351.
25. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
26. Winzell M.S., Ahrén B. G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. Pharmacol. Rev. 2007, 116:437-448.
27. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 2005, 11:2279-2299.
28. Yamagishi S., Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid. Med. Cell. Longev. 2010, 3:101-108.
29. Yamagishi S., Amano S., Inagaki Y., Okamoto T., Takeuchi M., Makita Z. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Mol. Med. 2002, 8:546-550.
30. Yamagishi S., Nakamura K., Ueda S., Kato S., Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res. 2005, 320:437-445.
31. Yamagishi S., Fukami K., Ueda S., Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug Targets 2007, 8:952-959.
32. Ye S.D., Zheng M., Zhao L.L., Qian Y., Yao X.M., Ren A., Li S.M., Jing C.Y. Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy. Eur. J. Clin. Invest. 2009, 39:980-985.